Korsana Therapeutics launched with $175 million in venture backing to develop KRSA‑028, an anti‑amyloid antibody aimed at Alzheimer’s disease; the financing was led by Wellington, Sanofi Ventures and other institutional investors. Korsana emerged from biotech spinout activity and plans a 2027 clinical start for its lead program. Investors cited renewed confidence in amyloid‑targeting approaches after recent regulatory approvals and commercial launches for similar modalities. Korsana’s cash position aims to carry the company through early clinical milestones and positioning for partnerships or further funding ahead of pivotal testing. The round underscores sustained investor appetite for Alzheimer’s antibody assets despite crowded competition and regulatory scrutiny; strategic differentiation, blood‑brain barrier activity and clinical differentiation will be critical to Korsana’s next inflection points.